Contineum Therapeutics (CTNM) Assets (2023 - 2025)
Historic Assets for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $190.8 million.
- Contineum Therapeutics' Assets fell 1165.88% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.8 million, marking a year-over-year decrease of 1165.88%. This contributed to the annual value of $212.8 million for FY2024, which is 6324.38% up from last year.
- Contineum Therapeutics' Assets amounted to $190.8 million in Q3 2025, which was down 1165.88% from $182.9 million recorded in Q2 2025.
- Contineum Therapeutics' Assets' 5-year high stood at $221.4 million during Q2 2024, with a 5-year trough of $123.6 million in Q1 2024.
- Its 3-year average for Assets is $184.5 million, with a median of $194.6 million in 2025.
- In the last 5 years, Contineum Therapeutics' Assets surged by 6324.38% in 2024 and then crashed by 1737.8% in 2025.
- Contineum Therapeutics' Assets (Quarter) stood at $130.4 million in 2023, then skyrocketed by 63.24% to $212.8 million in 2024, then dropped by 10.34% to $190.8 million in 2025.
- Its Assets stands at $190.8 million for Q3 2025, versus $182.9 million for Q2 2025 and $198.3 million for Q1 2025.